Copenhagen, Denmark — August 7, 2025 — Leads & Copy — SNIPR Biome ApS has announced the closing of a EUR 35 million Series B funding round. New investors include the Cystic Fibrosis Foundation and the German Federal Agency for Breakthrough Innovation (SPRIN-D), joining existing investors Lundbeckfonden BioCapital, North-East Family Office, and Wellington Partners. The funding will support the development of a CRISPR-Cas therapy targeting airway infections caused by Pseudomonas aeruginosa in cystic fibrosis patients and advance a CRISPR-based microbial intervention to eliminate antibiotic resistance genes in humans. Additionally, it will further the clinical development of SNIPR001 in patients with hematologic cancer, including the ongoing phase 1b trial.
Christian Grøndahl, CEO and Co-Founder of SNIPR BIOME, noted the importance of addressing antimicrobial resistance and infectious disease, highlighting SNIPR BIOME’s unique position in the development landscape.
SNIPR BIOME is pioneering the use of CRISPR-Cas technology for selective and precise killing of target bacteria and removal of antibiotic resistance genes, while preserving the patient’s microbial community. The technology is also used to create CRISPR-medicine for therapeutic conversion and production within targeted regions of the gastrointestinal tract.
SNIPR Biome is a Danish clinical-stage biotech company pioneering the development of CRISPR-medicine for treating and preventing human diseases through precision killing of bacteria or gene modification. SNIPR001 is currently being evaluated in a Phase 1b study (NCT06938867) at eight cancer centers in the US and is co-funded by CARB-X. SNIPR technology is used in collaborations with CARB-X, Gates Foundation, Cystic Fibrosis Foundation, IPATH, SPRIN-D, and MD Anderson Cancer Center.
Christian Grøndahl | +45 2020 2747 | cg@sniprbiome.com
Source: SNIPR Biome
